AbbVie Teams Up With Neomorph for Molecular Glue Collab Worth up to $1.64B

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.
In a licensing deal that could reach up to $1.64 billion, AbbVie is teaming up with Neomorph to develop molecular glue degraders, a modality that has caught Big Pharma’s attention of late, with Biogen, Novartis, Takeda and Novo Nordisk all striking deals last year and potentially throwing over $6 billion into the space. Biogen’s and Novo’s deals were also with Neomorph.